Nissan Motor Co., Ltd. remains a 'Buy' as its recent business restructuring and partnership with Honda are expected to enhance future financial performance. The company is expanding its Japanese product lineup supported by strong pre-orders, aiming to increase domestic sales. The alliance with Honda accelerates development of software-defined vehicles and improves cost efficiencies, which should help expand profit margins and speed up time-to-market for new models. These strategic moves position Nissan for stronger growth ahead.
Nissan Motor's market context shows a breadth of 105 priced Consumer Cyclical-sector US stocks tradable on Pluang, with 55 rising and 47 falling today. For readers following this sector, here is Pluang's market snapshot as of Sep 14, 2026 22:14 WIB: Domino's Pizza, Inc. (DPZ) rose 3.03% to USD 321.04, Bath & Body Works Inc (BBWI) fell 2.91% to USD 18.03, and Autozone Inc (AZO) increased 2.57% to USD 2,950.73.
Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...
The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...
W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...
GE Aerospace is set to report its Q3 earnings with analysts forecasting a 21.7% rise in earnings per share to $2.02 and nearly 12% revenue growth to about $12.7 billion. Despite consistently beating estimates, the stock has fallen after past reports ...
Silence Therapeutics' stock surged 125.6% to $19.58 following Merck KGaA's agreement to acquire the RNA-interference drug developer for about $1.3 billion in equity value. Merck will pay $20 per share, a 130% premium over the recent closing price. Ot...
